It is hoped that these reagents will help combat the growing wave of deaths in North America attributable to synthetic opioids
Funding secured from Bill and Melinda Gates Foundation to expand disease testing.
MIP Diagnostics, a UK nanotechnology business has secured increased investment of its previous round of funding, totalling £7.3M. The joint investment comes from Mercia Asset Management, Calculus Capital, Downing Ventures and BGF, along with an original angel investor.
MIP Diagnostics, which produces synthetic antibodies, has launched a new product that could improve the success of rapid sensors in detecting COVID-19. MIP Diagnostics has today announced the launch of its COVID-19 nanoMIP for diagnostic sensors, a synthetic alternative to antibodies that offers ultra-high sensitivity for the next wave of COVID-19 antigen detecting devices. nanoMIPs … Continued
MIP Diagnostics Ltd, the Molecularly Imprinted Polymers (MIPs) specialist based in Sharnbrook, United Kingdom, has announced a collaborative agreement with commercial partners for the co-development and license of a novel MIP-based system with specific applications in the security field. The long-term benefits of the deal could have ground breaking implications in the target applications and generate … Continued